Intranasal Drug Delivery - US Market Trends & Analysis

Intranasal Drug Delivery - US Market Trends & Analysis

The US intranasal drug delivery market is witnessing an expansion of therapeutic applications from the delivery of conventional local therapeutic drugs to the delivery of systemic therapeutic drugs. The future of the technology hinges onto the effective exploitation of the fact that the nose offers an en-route that bypasses the blood-brain barrier through the olfactory region. The market also stands enthused by the continuous research and development activities, which are gradually opening up opportunities in new therapeutic areas, such as, osteoporosis, pain management, vitamin B12 deficiency, smoking cessation, migraines, nocturnal enuresis, rheumatoid arthritis, sexual dysfunction, cancer therapy, insulin-dependent diabetes, and epilepsy.

These and other market data and trends are presented in "Intranasal Drug Delivery: US Market Trends & Analysis" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

INTRANASAL DRUG DELIVERY BMR-1067


CONTENTS


1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3

2. GLOBAL MARKET OVERVIEW AND OUTLOOK 3
Drug Delivery: A Quick Primer 3
The Nose: An Attractive Avenue to Cross the Blood Brain Barrier 4
Self-Administration of Drugs Brings Intranasal Drug Delivery
Into the Spotlight 5
Research & Technology Opens Up New Therapeutic Areas for
Nasal Drug Delivery 5
Recent Product Developments in the US Intranasal Drug
Delivery Market (2007) 6
R&D: Critical to the Commercialization of Intranasal Drug
Delivery 6
Tight Junction Biology: A Key Speed Breaker in
Commercialization 7
RNA Interference (RNAi): A Tool To Manipulate Tight Junctions 7
Why Is Nasal Drug Delivery the Theme of All Drug Delivery
Research Projects? 8
Nasal Drug Delivery Devices & Equipments Preservative Free
Systems (P.F.S.) 8
Traditional Vs Advanced Intranasal Drug Delivery Devices 10
Pitfalls Of Traditional Delivery Devices 10
The Promise of New Advanced Delivery Devices 10
Bi-Directional Nasal Drug Delivery: A Technology With a Huge
Potential 10
Benefits of Bi-Directional Delivery Authenticated Through
Research Studies 11
Market for Nasal Spray Devices in the US 12
GSK Wields the Leadership Scepter in the US Intranasal Drugs
Market 12
The Batting Order 13

3. MARKET DYNAMICS 13
Innovation in Drug Delivery: A Talisman for Success 13
Controlled Release Technology is the Buzz Word 13
Target-Specific Delivery Devices: Of Critical Value 14
Safety & Cost: Primary Growth Drivers 14
Preservatives Losing Sheen in Nasal Spray Formulations 14
Multi-Dose Containers Evolve to Offer Resistance Against
Microbial Contamination 15
Bioavailability: An Important Facet of Intranasal Drug Delivery 15
Chemical Modification 15
Transient Modification & Limited Enzymatic Activity 16
Bioavailability of Large Molecules 16
Bio-Adhesive Polymers: Useful in Increasing Drug Absorption 16
Mixed Opinions on Efficiency of Calcitonin Nasal Spray 16
Nasal Preparations Gaining Foothold in Cough and Allergic
Categories 17
Patent Expiries Impact Market Opportunities 17

4. PRODUCT FACTS 19

5. RECENT TECHNOLOGICAL DEVELOPMENTS 20
New-Generation Technologies and Devices 21
ViaNase from Kurve Technology 21
A New Product from OptiNose 21
Nastech’s “Tight Junction Biology” Research Program 22
ChiSys™ Nasal Delivery Technology from Archimedes 22

6. CORPORATE DEVELOPMENTS 23
Zelos Therapeutics Collaborates with Aegis Therapeutics 23
ImmuneRegen BioSciences Partners with LRRI 23
Avamys™ Nasal Spray Receives Approval in Europe 23
PMI-150 Receives Canadian Patent 23
Nastech Enrolls 551 Patients for Phase 2 Trials of PYY3-36
Nasal Spray 24
USFDA Approves FluMist® for Young Children 24
USFDA Approves Veramyst Nasal Spray for Individuals Aged Two
Years and Above 24
Kurve Technology Inks Agreement with Schering-Plough 24
MedImmune Clarifies FDA Observations 25
FluMist(R) Receives FDA Approval for Refrigerated Formulation 25
Nastech Regains Rights for PTH1-34 Nasal Spray 25
NASONEX(R) Receives Ease-of-Use Commendation from Arthritis
Foundation 25
Aegis Therapeutics Establishes Cedar Therapeutics Inc. 25
EMEA Provides Encouraging Feedback for Avamys™ Nasal Spray 25
Kurve Technologies Introduces Blog on Nasal Drug Delivery 26
Archimedes Pharma Commences Phase III Trials for NasalFent® 26
Archimedes Presents New Clinical Data on NasalFent® 26
LigoCyte Commences Clinical Trials for Intranasal Norovirus
Vaccine 27
Javelin Pharmaceuticals Reveals Phase 2 Study Results for PMI
-100/150 27
Javelin Pharmaceuticals Commences Phase III Studies for PMI-150 27
Nastech Commences Phase 2 Trials for Insulin Nasal Spray 27
ACAAI Reveals Results for Trials of Nasacort® AQ Nasal Spray
in Children 28

7. MAJOR PLAYERS 28
Aegis Therapeutics LLC (USA) 28
Alza Corporation (USA) 28
AptarGroup, Inc. (USA) 29
Archimedes Pharma Limited. (UK) 29
AstraZeneca Plc (UK) 29
MedImmune, Inc. (USA) 29
Bayer Consumer Care (USA) 30
Bespak Plc (UK) 30
GlaxoSmithKline Plc (UK) 30
Intranasal Therapeutics, Inc. (USA) 30
Javelin Pharmaceuticals, Inc (USA) 31
Kurve Technology, Inc. (USA) 31
MDRNA, Inc. (USA) 31
Novartis AG (Switzerland) 31
OptiNose AS (Norway) 32
Pfizer, Inc. (USA) 32
Rexam Plc (UK) 32
Schering-Plough Corporation (USA) 32
Sanofi-Aventis S.A. (France) 32
Unigene Laboratories, Inc. (USA) 33

8. MARKET ANALYTICS 33


EXHIBITS

Table 1: The US Nasal Drug Delivery Market: Sales Of Top Six
Nasal Formulations for The Year 2005 (In US$ Million)

Table 2: Percentage Market Shares of Leading Intranasal Drug
Delivery Players in the US - 2006

Table 3: Percentage Shares of Intranasal Drugs Manufacturer
Value in the US - 2012

Table 4: Top 10 Nasal Sprays, Drops and Inhalers Brands Ranked
by Dollar Sales Through Drug Stores in the US - 2008 (In US $
Million)

Table 5: Top 10 Nasal Sprays, Drops and Inhalers Brands Ranked
by Unit Sales through Drug Stores in the US - 2008 (In
Thousand Units)

Table 6: Top Five Nasal Sprays Ranked by Dollar Retail Sales
in the US - 2008 (In US $ Million)

Table 7: Projected Revenues for Intranasal Sexual Dysfunction
Drugs in the US -2010, 2011 & 2012 (in US$ Million)

Table 8: Intranasal Drug Delivery Market by Therapeutic Area
in the US: 2007-2015 (Sales in US$ Million)

Table 9: Percentage Breakdown of Intranasal Drug Delivery
Market by Therapeutic Area in the US for the Years 2008 & 2012


COMPANIES PROFILED